Follow-up of children exposed antenatally to immunosuppressive drugs.

M. Motta, A. Tincani, P. L. Meroni, R. Cimaz

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Antenatal exposure to immunosuppressive drugs given to mothers during pregnancy to treat autoimmune diseases raises some questions about the fetal development and the long-term outcome of children. Studies in humans showed that glucocorticoids (GCs), CsA and HCQ do not seem to increase the risk of congenital abnormalities; in contrast, cyclophosphamide, LEF and MTX are contraindicated during pregnancy. The risk of gestational complications, including pre-term delivery, intrauterine growth retardation (IUGR) and low birth weight (LBW), is higher in autoimmune diseases rather than in the general population and probably this finding is related to both maternal disorder and immunosuppressive therapy. Recently, results of our studies suggest that immunosuppressants given during pregnancy do not impair significantly the development of immunity in exposed children. Moreover, preliminary data on neurodevelopmental outcome seem to exclude a causative role of in utero exposure to immunosuppressive agents on the cognitive impairment observed in some of these children; however, our data need to be confirmed with further observations.

Original languageEnglish
JournalRheumatology
Volume47 Suppl 3
Publication statusPublished - Jun 2008

Fingerprint

Immunosuppressive Agents
Pharmaceutical Preparations
Pregnancy
Autoimmune Diseases
Mothers
Fetal Growth Retardation
Low Birth Weight Infant
Fetal Development
Cyclophosphamide
Glucocorticoids
Immunity
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Follow-up of children exposed antenatally to immunosuppressive drugs. / Motta, M.; Tincani, A.; Meroni, P. L.; Cimaz, R.

In: Rheumatology, Vol. 47 Suppl 3, 06.2008.

Research output: Contribution to journalArticle

Motta, M. ; Tincani, A. ; Meroni, P. L. ; Cimaz, R. / Follow-up of children exposed antenatally to immunosuppressive drugs. In: Rheumatology. 2008 ; Vol. 47 Suppl 3.
@article{5b3ffedd3b07443a98b9ad8d24557e66,
title = "Follow-up of children exposed antenatally to immunosuppressive drugs.",
abstract = "Antenatal exposure to immunosuppressive drugs given to mothers during pregnancy to treat autoimmune diseases raises some questions about the fetal development and the long-term outcome of children. Studies in humans showed that glucocorticoids (GCs), CsA and HCQ do not seem to increase the risk of congenital abnormalities; in contrast, cyclophosphamide, LEF and MTX are contraindicated during pregnancy. The risk of gestational complications, including pre-term delivery, intrauterine growth retardation (IUGR) and low birth weight (LBW), is higher in autoimmune diseases rather than in the general population and probably this finding is related to both maternal disorder and immunosuppressive therapy. Recently, results of our studies suggest that immunosuppressants given during pregnancy do not impair significantly the development of immunity in exposed children. Moreover, preliminary data on neurodevelopmental outcome seem to exclude a causative role of in utero exposure to immunosuppressive agents on the cognitive impairment observed in some of these children; however, our data need to be confirmed with further observations.",
author = "M. Motta and A. Tincani and Meroni, {P. L.} and R. Cimaz",
year = "2008",
month = "6",
language = "English",
volume = "47 Suppl 3",
journal = "Rheumatology",
issn = "1462-0324",
publisher = ". Published by Oxford University Press on behalf of the British Society for Rheumatology",

}

TY - JOUR

T1 - Follow-up of children exposed antenatally to immunosuppressive drugs.

AU - Motta, M.

AU - Tincani, A.

AU - Meroni, P. L.

AU - Cimaz, R.

PY - 2008/6

Y1 - 2008/6

N2 - Antenatal exposure to immunosuppressive drugs given to mothers during pregnancy to treat autoimmune diseases raises some questions about the fetal development and the long-term outcome of children. Studies in humans showed that glucocorticoids (GCs), CsA and HCQ do not seem to increase the risk of congenital abnormalities; in contrast, cyclophosphamide, LEF and MTX are contraindicated during pregnancy. The risk of gestational complications, including pre-term delivery, intrauterine growth retardation (IUGR) and low birth weight (LBW), is higher in autoimmune diseases rather than in the general population and probably this finding is related to both maternal disorder and immunosuppressive therapy. Recently, results of our studies suggest that immunosuppressants given during pregnancy do not impair significantly the development of immunity in exposed children. Moreover, preliminary data on neurodevelopmental outcome seem to exclude a causative role of in utero exposure to immunosuppressive agents on the cognitive impairment observed in some of these children; however, our data need to be confirmed with further observations.

AB - Antenatal exposure to immunosuppressive drugs given to mothers during pregnancy to treat autoimmune diseases raises some questions about the fetal development and the long-term outcome of children. Studies in humans showed that glucocorticoids (GCs), CsA and HCQ do not seem to increase the risk of congenital abnormalities; in contrast, cyclophosphamide, LEF and MTX are contraindicated during pregnancy. The risk of gestational complications, including pre-term delivery, intrauterine growth retardation (IUGR) and low birth weight (LBW), is higher in autoimmune diseases rather than in the general population and probably this finding is related to both maternal disorder and immunosuppressive therapy. Recently, results of our studies suggest that immunosuppressants given during pregnancy do not impair significantly the development of immunity in exposed children. Moreover, preliminary data on neurodevelopmental outcome seem to exclude a causative role of in utero exposure to immunosuppressive agents on the cognitive impairment observed in some of these children; however, our data need to be confirmed with further observations.

UR - http://www.scopus.com/inward/record.url?scp=67650672350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650672350&partnerID=8YFLogxK

M3 - Article

C2 - 18504283

AN - SCOPUS:67650672350

VL - 47 Suppl 3

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

ER -